Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYanping SunFLFei LuJYJingjing Ye

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows blinatumomab improves MRD clearance and progression-free survival in newly diagnosed B-ALL, suggesting better outcomes compared to relapsed disease.

Key Points

  • The research aims to compare blinatumomab efficacy on MRD clearance and survival rates between newly diagnosed and relapsed/refractory B-ALL.
  • Conducted a multicenter retrospective analysis of 113 adult B-ALL patients
  • MRD was assessed by flow cytometry and PCR for BCR::ABL1 transcripts
  • Primary endpoints: complete remission and progression-free survival; secondary endpoints: overall survival and MRD negativity
  • Comparison of groups used statistical tests including Fisher's test and Kaplan-Meier survival analysis
  • All newly diagnosed patients achieved complete remission, significantly higher than the relapsed group.
  • 83.3% flow-MRD negativity occurred in the induction group.
  • 12-month PFS and OS rates were 100% for MRD-negative patients in the newly diagnosed subgroup.
  • Cytokine release syndrome was observed in 4.4% of patients, while neutropenia affected 57.5%.

Cite This Study

Sun et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d559https://doi.org/10.1182/blood-2025-6307
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher2025
  2. 2Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  3. 3“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025
  4. 4Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025
  5. 5The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease2024